The equine immune response to equine herpesvirus-1: The virus and its vaccines

Kydd, Julia H.; Townsend, H. G. G.; Hannant, D.

doi:10.1016/j.vetimm.2006.01.005

Cited by 105 publications

(108 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although vaccines against EHV-1 are available, they are not fully protective (Kydd et al, 2006;Goodman et al, 2006;van der Meulen et al, 2006a) and outbreaks of disease may still occur (Buchner and Mostl, 1998;Friday et al, 2000;van der Meulen et al, 2000;Kohn et al, 2003;Goehring et al, 2006). Therefore, there is a need for effective antiviral chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet

Garré

Meulen

Nugent

et al. 2007

Veterinary Microbiology

View full text Add to dashboard Cite

Equine herpesvirus 1 (EHV-1) is an important equine pathogen that causes respiratory disease, abortion, neonatal death and paralysis. Although vaccines are available, they are not fully protective and outbreaks of disease may occur in vaccinated herds. Therefore, there is an urgent need for effective antiviral treatment. For three abortigenic (94P247, 97P70 and 99P96) and three neuropathogenic isolates (97P82, 99P136 and 03P37), the effect of acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet on plaque number was studied. Additionally, for isolate 97P70, the effect on plaque size was investigated. Ganciclovir was most potent in reducing plaque number, followed by PMEDAP and acyclovir. Adefovir and cidofovir were less effective and foscarnet was the least effective compound. There were no differences detected for acyclovir, ganciclovir, adefovir and PMEDAP between the abortigenic and neuropathogenic isolates. One abortigenic isolate (99P96) was more susceptible to cidofovir and two neuropathogenic isolates (99P136 and 03P37) were less susceptible to foscarnet. For isolate 97P70, all compounds resulted in a significant reduction of plaque size. The most remarkable effect was observed for cidofovir. It was 40-fold more effective in reducing plaque size than in reducing plaque number. In conclusion, ganciclovir was the most potent compound and therefore, may be a valuable candidate for the treatment of EHV-1 infections in horses. The antiviral effect of foscarnet on plaque number was highly dependent on the viral isolate tested. Therefore, it is no valuable antiviral for the treatment of herpesvirus-infections. Cidofovir, although less effective in reducing plaque number, had a strong effect on plaque size. #

show abstract

Section: Introductionmentioning

confidence: 99%

In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet

Garré

Meulen

Nugent

et al. 2007

Veterinary Microbiology

View full text Add to dashboard Cite

show abstract

“…Es así, que los anticuerpos detectados en estos caballos podrían ser de origen vacunal como lo indica la seropositividad detectada en estos animales. Además, los títu-los de los anticuerpos corresponden al rango de títulos inducidos por vacuna inactivada que usualmente no son títulos altos (Kidd et al, 2006). El 90% de caballos de carrera seropositivos evidencia que los caballos fueron vacunados, mientras que la moderada seropositividad detectada en los caballos Peruano de Paso y de equitación podría indicar que no todos los criadores utilizan la vacuna para prevenir esta infección viral.…”

Section: Discussionunclassified

Seroprevalencia del Virus de la Rinoneumonitis en Caballos (Equus caballus) del Perú

Galindo

Rivera

Ramírez

et al. 2015

Rev. investig. vet. Perú

View full text Add to dashboard Cite

El objetivo del presente estudio fue determinar la seroprevalencia del virus Herpes Equino tipo 1 o Herpes Equino tipo 4 (VHE-1/VHE-4), causante de la rinoneumonitis viral en caballos. Se recolectaron muestras de suero (n=825) de caballos mayores a seis meses de edad, entre machos y hembras, identificados como caballos de crianza familiar, de carrera, Peruano de Paso y de equitación, clínicamente normales, provenientes de varias regiones del Perú, para la detección de anticuerpos neutralizantes contra el VHE-1/VHE- 4 mediante la prueba de neutralización viral. El 48.9 ± 5.3% (403/825) de las muestras tuvieron anticuerpos contra el VHE-1/VHE-4. Los títulos de anticuerpos tuvieron un rango entre 2 a >256, siendo de 58.6% de títulos de 2 a 8, de 29.5% en títulos de 16 a 64, y de 11.9% en títulos de 128 a >256. La prueba de regresión logística indicó que las variables sexo y lugar de procedencia no constituyeron factores de riesgo para la presentación de anticuerpos contra el VHE-1/VHE-4.

show abstract

“…It may cause respiratory disease, sporadic or epizootic abortions, or, recently more often, neurological disease known as equine herpesvirus myeloencephalopathy (EHM), which may be life-threatening and results in significant economic losses to the equine industry (1,13,15,18,19).…”

Section: Praca Oryginalnamentioning

confidence: 99%

“…It has been suggested that a single-nucleotide polymorphism in the EHV-1 DNA polymerase gene, which leads to amino acid variation (N752/D752), may be associated with outbreaks of EHM (3,11,13). D752 strains of EHV-1, which are statistically more often isolated from cases of EHM, were called neuropathogenic strains.…”

Section: Praca Oryginalnamentioning

confidence: 99%

Acyclovir and trichostatin A modulate EHV-1 replication in murine neurons in vitro

Golke¹,

Cymerys²,

Tucholska³

et al. 2017

Medycyna Weterynaryjna

View full text Add to dashboard Cite

SummaryEquine herpesvirus type 1 (EHV-1) is a major viral pathogen of horses, causing respiratory disease, abortions, and equine herpes myeloencephalopathy (EHM). Like other alphaherpesviruses, EHV-1 establishes latency in neurons, but mechanisms involved in this process are still elusive. In the present study, we used antiviral drug acyclovir (ACV) to completely suppress EHV-1 replication in primary murine neuron culture. Trichostatin A (TSA), a known chemical reactivator of other herpesviruses, was used to stimulate productive EHV-1 infection. Moreover, gene expression of some cytokines was simultaneously evaluated, in order to check, whether the maintenance conditions of such a model may influence host cell response. Changes observed in IFN-α, IFN-β, and IL-10 mRNA gene expression depended on the EHV-1 strain. Although infection with either of the two EHV-1 strains investigated led to in an increase in type I IFNs gene expression, only the neuropathogenic strain caused a decrease in anti-inflammatory IL-10 gene expression. Unlike EHV-1 infection, the addition of neither ACV nor TSA caused significant changes in the expression of the above genes. We may therefore conclude that the in vitro model presented in the study is suitable for detailed investigation of the host cell-virus relationship on the molecular level.

show abstract

The equine immune response to equine herpesvirus-1: The virus and its vaccines

Cited by 105 publications

References 57 publications

In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet

In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet

Seroprevalencia del Virus de la Rinoneumonitis en Caballos (Equus caballus) del Perú

Acyclovir and trichostatin A modulate EHV-1 replication in murine neurons in vitro

Contact Info

Product

Resources

About